0001493152-23-029242.txt : 20230817 0001493152-23-029242.hdr.sgml : 20230817 20230817083808 ACCESSION NUMBER: 0001493152-23-029242 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230815 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230817 DATE AS OF CHANGE: 20230817 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOTRICITY INC. CENTRAL INDEX KEY: 0001630113 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 472548273 STATE OF INCORPORATION: NV FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40761 FILM NUMBER: 231179888 BUSINESS ADDRESS: STREET 1: 203 REDWOOD PARKWAY STREET 2: SUITE 600 CITY: REDWOOD CITY STATE: CA ZIP: 94065 BUSINESS PHONE: (650) 832-1626 MAIL ADDRESS: STREET 1: 203 REDWOOD PARKWAY STREET 2: SUITE 600 CITY: REDWOOD CITY STATE: CA ZIP: 94065 FORMER COMPANY: FORMER CONFORMED NAME: METASOLUTIONS, INC. DATE OF NAME CHANGE: 20150107 8-K 1 form8-k.htm
0001630113 false 0001630113 2023-08-15 2023-08-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): August 15, 2023

 

BIOTRICITY INC.

 

(Exact name of registrant as specified in its charter)

 

Nevada   001-40761   30-0983531

(State or Other Jurisdiction of

Incorporation or Organization)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

203 Redwood Shores Parkway, Suite 600

Redwood City, California 94065

(Address of Principal Executive Offices)

 

(650) 832-1626

(Registrant’s telephone number, including area code)

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act: None

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 2.02 Results of Operations and Financial Condition.

 

On August 15, 2023, Biotricity Inc. (the “Company”) issued a press release reporting its financial results for the period ended June 30, 2023. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

The information in this Current Report, including the exhibits hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the accompanying Exhibit 99.1 shall not be incorporated by reference into any registration statement or other document filed by the Company with the Securities and Exchange Commission, whether made before or after the date of this report, regardless of any general incorporation language in such filing (or any reference to this Current Report on Form 8-K generally), except as shall be expressly set forth by specific reference in such filing.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit Number   Description
99.1   Press Release dated August 15, 2023
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

Date: August 17, 2023

 

  BIOTRICITY INC.
     
  By: /s/ Waqaas Al-Siddiq
    Waqaas Al-Siddiq
    Chief Financial Officer

 

 

 EX-99.1 2 ex99-1.htm

 

Exhibit 99.1

 

Biotricity Reports Strong Growth for its First Quarter Fiscal Year 2024 and Provides Financial Results and Business Updates

 

 

REDWOOD CITY, CA / ACCESSWIRE / August 15, 2023 / Biotricity Inc. (NASDAQ:BTCY) (“Biotricity” or the “Company”), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, today announced its financial results for the first quarter of fiscal 2024 year ended June 30, 2023.

 

● Company reports Q1-FY24 revenue grew by 46.9% YOY to $3.0 million; continuing to advance toward positive cashflow
   
● Recurring technology fees and customer device sales, continue to trend higher
   
● Reduced SG&A to $3.5 million, down 22% compared to same period last year
   
● Gross margins improve to 63.5% from 59.6% in the same period last year
   
● Recurring Technology Fee revenue - over 90% of total revenue with a 72% gross margin — rose a robust 47% YOY
   
● Net loss improved 28% to $3.6 million
   
● Company will host its Q1 Fiscal Year 2024 Financial Results Call on Tuesday, August 15th at 4:30 p.m. ET

 

Dr. Waqaas Al-Siddiq, Biotricity Founder & CEO, commented, “Our first quarter fiscal 2024 marked a strong start to the year. We saw growth in our sales, encompassing technology fees and device sales. This achievement directly stems from our prudent fiscal management aimed at bolstering our bottom line, and the effective execution by our team and sales channels. Given our consistent gross margin on technology fees of approximately 70%, and an evolving revenue mix where technology fees are expected to comprise an increasing proportion of revenue, we anticipate continued improvement in overall blended gross margin over time. Our AI segment has begun to demonstrate progress and we’ve announced our strengthened relationships with Amazon and Google. We are committed to expanding our AI technology development into remote cardiac care with a focus on predictive monitoring tools to enhance disease profiling, improve patient management, and revolutionize the healthcare industry for disease prevention. In the future, we envision our cardiac AI model’s capacities will empower us to assist healthcare experts in efficiently managing a significantly higher patient load while discerning the most vital data points. This advancement will enable healthcare providers to enhance the caliber of care they deliver while catering to a more extensive patient base.Looking towards the rest of CY 2023, our focus remains four-fold: to increase sales of our remote cardiac monitoring solutions, ramp-up of our subscription-based service, accelerate our recurring revenue, and continue to draw a clear path to profitability.”

 

Dr. Al-Siddiq continued, “Our products, biosphere platform model, and vertical sales strategy of complementary products, continues to strengthen. Our Biocare app has received thousands of downloads and our BiotresTM- continues to attract industrywide interest with new and existing customers.We will continue to innovate and leverage data intelligently and explore novel approaches for enhancing healthcare outcomes. Through our ongoing commitment to cutting-edge research and development, we aim to redefine the landscape of medical diagnostics and patient care. With each passing quarter, we continue to substantiate our approach of constructing a resilient growth company through the expansion of subscription revenue, robust gross margins, and, over time, the establishment of a solid free cash flow model.”

 

 

 

 

Q1-FY24 Financial Highlights

 

● Revenue increased 46.9% to $3.02 million compared with $2.06 million in Q1 FY24
   
● Gross profit percentage was 63.5% for the three months ended June 30, 2023, as compared to 59.6% in the corresponding prior year quarter. This increase in gross margin was largely attributed to an increase in margin related to technology fees
   
● Net loss decreased 28% YOY to $3.6 million, or $0.069 per share, from a net loss of $5.0 million, or $0.098 per share, in Q1-FY23

 

Operating Highlights for Q1-FY24

 

● Q1-FY24 recurring (TaaS) Technology Fees rose a robust 47% YOY to $2.8 million, representing over 10 times Device Sales revenue
   
● Company maintains its impressive track record with a near-perfect customer retention rate of approximately 98%, consequently bolstering recurring revenue from Technology Fees
   
● Increased total addressable market from $1 billion to approximately $35 billion through the launch of its full line of cardiac monitors; and increased total addressable market as AI in the healthcare market is projected to grow to $208.2 billion by 2030
   
● Continued to expand its sales force network, with geographic footprint across 35 states with over 2,500 cardiologists
   
● Growing repeat sales to installed customer base with new complementary products and a lower cost of sales
   
● Company is driven to reach positive cash flow, driving revenue higher while reducing or holding SG&A stable

 

Full details of the Company’s financial results will be filed with the SEC on Form 10-Q and available by visiting www.sec.gov .

 

Financial Results and Business Update Conference Call

 

Management will host a conference call on Tuesday, August 15, 2023 at 4:30 p.m. ET to discuss its financial results for the fiscal 2024 first quarter and provide a business update. Additional details are available under the Investor Relations section of the Company’s website: https://www.biotricity.com/investors/

 

 

 

 

Event: Biotricity Q1-FY24 Financial Results and Business Update Call

Date: Tuesday, August 15th

Time: 4:30 p.m. ET (1:30 p.m. PT)

 

Toll Free: 877-405-1216

International: +1 201-689-8336

Webcast URL: https://event.choruscall.com/mediaframe/webcast.html?webcastid=I3WLbWnM

 

Investors can begin accessing the webcast 15 minutes before the call, where an operator will register your name and organization. The call will be in listen-only mode.

 

A replay of the call will be available approximately 3 hours after the live call via the Investors section of the Biotricity website at https://www.biotricity.com/investors/.

 

Toll Free Replay Number: 877-660-6853

International: 201-612-7415

Replay Access ID: 13740622

Expiration: August 29, 2023, 11:59 PM ET

 

About Biotricity Inc.

 

Biotricity is reforming the healthcare market by bridging the gap in remote monitoring and chronic care management. Doctors and patients trust Biotricity’s unparalleled standard for preventive & personal care, including diagnostic and post-diagnostic solutions for chronic conditions. The Company develops comprehensive remote health monitoring solutions for the medical and consumer markets. To learn more, visit www.biotricity.com.

 

Important Cautions Regarding Forward-Looking Statements

 

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words “may,” “should,” “would,” “will,” “could,” “scheduled,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “seek,” “project,” or “goal” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans, objectives and goals of management for future operations, including plans, objectives or goals relating to the design, development and commercialization of Bioflux or any of the Company’s other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company’s future financial performance, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company’s inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company’s inability to expand the Company’s business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company’s failure to implement the Company’s business plans or strategies. These and other factors are identified and described in more detail in the Company’s filings with the SEC. There cannot be any assurance that the Company will ever become profitable. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.

 

Contacts

 

Investor Relations

 

Biotricity Investor Relations

Investors@biotricity.com

 

SOURCE: Biotricity, Inc.

 

 

 GRAPHIC 3 ex99-1_001.jpg begin 644 ex99-1_001.jpg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�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end EX-101.SCH 4 btcy-20230815.xsd INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 btcy-20230815_lab.xml INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 btcy-20230815_pre.xml INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Cover
Aug. 15, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 15, 2023
Entity File Number 001-40761
Entity Registrant Name BIOTRICITY INC.
Entity Central Index Key 0001630113
Entity Tax Identification Number 30-0983531
Entity Incorporation, State or Country Code NV
Entity Address, Address Line One 203 Redwood Shores Parkway
Entity Address, Address Line Two Suite 600
Entity Address, City or Town Redwood City
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94065
City Area Code (650)
Local Phone Number 832-1626
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
XML 8 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001630113 2023-08-15 2023-08-15 iso4217:USD shares iso4217:USD shares 0001630113 false 8-K 2023-08-15 BIOTRICITY INC. NV 001-40761 30-0983531 203 Redwood Shores Parkway Suite 600 Redwood City CA 94065 (650) 832-1626 false false false false false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 1 20 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://biotricity.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm btcy-20230815.xsd btcy-20230815_lab.xml btcy-20230815_pre.xml ex99-1.htm http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form8-k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 20 }, "contextCount": 1, "dts": { "inline": { "local": [ "form8-k.htm" ] }, "labelLink": { "local": [ "btcy-20230815_lab.xml" ] }, "presentationLink": { "local": [ "btcy-20230815_pre.xml" ] }, "schema": { "local": [ "btcy-20230815.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 20, "memberCustom": 0, "memberStandard": 0, "nsprefix": "BTCY", "nsuri": "http://biotricity.com/20230815", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "AsOf2023-08-15", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://biotricity.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "AsOf2023-08-15", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://biotricity.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0001493152-23-029242-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-23-029242-xbrl.zip M4$L#!!0 ( ,1$$5=UX4L_+ , .D+ 1 8G1C>2TR,#(S,#@Q-2YX M],_T'UNRT,0QH()).0)J5#TA1R[4M'M@5H8DN.)&/HUU?R MC8N! &UYDG?/.;OKW95IG4T#'TPP%X31MF%;%0-@ZC*/T%';>!B8YX-.MVN ML]./'X#ZM3Z9)K@BV/>:X)*Y9I<.V0FX10%N@FM,,4>2\1/PB/Q(6]@5\3$' M'1:$/I98.=)(35"W[(8#3','W4=,/<8?^MU"=RQE*)H0QG%L439!,>.OPG)9 ML)O@0"(9B4*M,JUDO]WH-T2X!;EQ=!.*S],^>1YA>AQ=(AJ+)_1V3IR[QN_Z MS^,W_#J>/%U IQ\&.<8" :@85;4/7 MEY47URS&1[!:J=CP^:8W2'!&"FQ.?4)?U\'M1J,!$V\.+2&G#O=SZ1K4;@<) M7"@K+]F")U1(1-TEO"<+PB*X#E/G$I2LA1ZE4))#/;R"$]BU1FP"E4/AJ[4< M& ESA%!8@(=(.(EHYE@""R[+0&52K5-XBY),AP9X!).(C+/68B1"Y^%V]?%H1 MI4P-M=JLS*)M84C4U!8&9=)=;G+FXWN5/M 'M56;@F@W[#!U-QB >&TC/2[( MY8(>'A)*DN#9'MG U%L3Z5+5,6&VX"JXK!0)['VGI\DYY%@H>E)43QDR?@;9 MSG61[T;^0=1Y?MN8F3U_E:5WG*]3'P]!LH9-/3!M0Q!]$1J9;4=_J;(M-5 Y1$?8LH9)CU;?5!8XET#<+:F4K@DEPD+,)5%3O7 7I*D3J>EW M"V& CB,, /]AY3YR]JU<4;#_'TON:?URK2VXO%OJ>77_6JI=I>F M7X$>' M9(1V#;KAR[ UZ%H.Q+X4N>7@%!:_(W^10R*S5Q)+[?0DAUI"BU9-U<>:O3F= M]YC)LSAH"%P64ZJ7XF*2^CC_]N-M0]$)$ MFG!V/IH>?1PAPB(>)VQ]/OJZ&%\L9O/Y"*499C&FG)'S$>.C'W_X\Y^0_//I MN_$8726$QF?H"X_&<_; OT$/.T$^$$8$S+KY'WS#=JBW\*J%$H!G?/%.2 M$5E0[/@,_?UH>KI"X_& >K\1%G/Q]7Y>U?N89<_IV63R^OIZQ/@+?N7B*3V* M^&98A8L,9]NTJNWC[F/YIPC_1!/V=*;^6N&4('F\6'JV2Y/SD=ION=O7DR,N MUI/CCQ^GDW_^GD[R4BUM*782SO-M[=X- A?K?6,O&:M-X>CP^F1[MTGBD#WY^ M! 6GY)X\H+R99]G^6:*4)HJ$4;GM49 'NQDJQ$3%3QA9XXS$:D>G:D?3?Z@= M_:7.W'E:J-U_)3 MPR+997("([$VJ:KH&('S/>030UEW53N/&O52-9IST6Z[FAGS.E,2':WYRR0F MB:S[^$1]&*L/>;/E?_Z8<;D2N%BEF2&T+RRBGL:5 MBDG$Y=3TG(UI<1B+\ ?!-];=EJWFEL(_Z*J*+PZ+W 5@M"$3).5;$9$W]4K= M+7242D<;*A5J2478^.MB]$.N0;]KU7\^30ZU..AHN03:;@C+EK)&2PN:Q:ZZ MV69*]W*]+(A.MA@R^UA+D-(X[N +N>-8[?R*XK7%OE'NJHNMMG0?-PJ#Z&2; M([.7*PU2(E_=_(6DD4B>U7*^JQT-F?-.MYAL]7U-$Q8";6,P"36MIX']GJP3 M-;4H"^K\EJB-'<,8H'<]]'?:-N<"JS@(:(8X!&>+>A"JHCQQ=,'8%M-[\LQ% M%SY-F6MJ;"9-6.J:H!BQ& /1*+2H$'LBXM>M/&,G@NY[H6@I77,!6#71,&1! MT6'W!@)2R?TRLA28I8D:P'HA:4N=GVX 9ENG'H8N*$X <_ I2:7W2\KBD5"J M[@=@UC^@V,2N:8$-F[RTE4$1 ]H#FI2A .)K.^M"0:I]@7"5IA&GAY4IN2SN:9]&Z!@2T:T+2 M$@8%"N0.A*4(T,SD(5Z!^1?!8A@N-:4?6%I6[:A4L@!!,;WU8:+T7B"9;85H MN(9G'%CJ[*9LC]GJ_BR@"P*4'G.MN[:%O &*IQGHDF5)ME?/T]UL-RLB+(UK M2URQ 9G33)CE0; F#(9*&1(Z5 A]-+S^BX!R]1#C&!S3)E; NPFFQ0T-0&1 M8#4&T'#0YL^4>B%B)DF+=/):@ M)@])\3QX#R6@WBTL/;:;S #B@-#I=@@0)(-0,\HG2',6H\GKP"I&KP0=Q''\D"E MY3_7"2-3L/U6K5NZ.NPVF;(( R()=@?P4RH_Z ](Q:!;%@HTQV]HZK%_:(Z' M0G,<-#3'[X%F^;D#4T]\0_-R5!H3H*&YN1=T,B.]SK6S.3'6['DK[:' MLT&E%V3:5JW '&3AX=+RU@>+"E#K&17B$Y-\874K[@1_25@$+YDAN1=@ --6 M:@QM>.C8#?;Q4RV(=9S7L:98E/=^2;3,SRC3-&D?8@I->) TC?4.+H7:)Q)W M/,TP_7?RW'DB;A=[P<-JV I)0QD>*C9[?< 4,4@&^3BQ+G%5-S2LKY(9Y>Y> M ;;8.KP"7"L, @*;H_8KP,75DT+DNIL5HX)@8$1H%COK9(NIJH]K96%T<=M0 MJX?S[[74^/@BJ^PN].Z1,_@!@;;$54]#YG1OF^5!]#A@RNSU7(9RG:>K\2K# M1&H?OFMESF9VTTXUD>N"('K7=-.:IG6YX][\3229W/.,;S9;5M[EL3TW".A< M]7*G3=WC5E$0O=_ES"2AU**FV#$6"TZ3*,D2MOY%GGR*!-M:91.Y @(VJ&EH M*X) ;1E *FE#Q$GR&0O5$6@3[86 M)-K*^7$_/5XMDXS:3B[;$F=S$F"NFI&,\B#8 $R9+.1EB#^@Z?%?5W]#.LIQ M]]_PI< J>>QBOUEQ"F2?LJI<0=!A47-@D02! NS+I.&&HU**"JV/[%0-LY;F M&.6N +#:TEW?* RBTVV.6E_^1E][&O(O=]&C-$6 %Q+L,M=#O\VD.?S7-4$@ MT&&L=5)22I'6^G@AX3!EK?L7 6MOBX!USR)@'>(B8#UT$;#VM@C0NRU2A,AQ MZ79%DS4&DA-VJEU#T6'9Y,,B#0H5V!\X9E0AZ!#C.J-EGN),I><7FWS_5_*# MI96 SEE.RRZ;55)+FR@(1KJ\.@0V$ MY(Y?U^XT;;RU;=4&Q$RG0>@=[C+GQV%M7$1Y>L4R(^KW(I(7\@5GN/0&MA>2 MNWZILLNT^3:E31L00IT&P?6%AL,*6?MVG"2 I/1(;*+0M6BTT6&I* 6+#Y EC( MI4AKO;!PN2%B+:>WGP1_S1[+_*Q@VP"U6S8Z+3<9L4H#8J7+'\",#D%%C$ZI MZP>>W2&A>)%E$6ZI1>H8&]"LP4Q+%Q(PD+D6+91$ZGK+#<_0DJ.O*4'9(T&7 MY<_0U3/!%_7X^J61*%(O1!2KD0WXMD-_B"N"AIK7'/7I@Z!IH$F3J3RL>7*=!R(5 MZ3.;43VY/;S$:X@D2SO( B(@+8K*$5>+D2YTDO_?\;L26R?LVA_)WA$B'K**JU&J[[K M;P.CW3+SIB8U:1H4&A!G;_$+$'BH M7J^%";L7Q>S%,/C:ML;CQZ6CQB>0!O MMUFJ9E!I#+X*WAGD^/;"@ 88-QDZ(@)";X!-Z(9#'HGRT ^H"$:U:$_G9^DA M"R")/^_OR0,1ZKV#)=EEG^6.GCK., ;$NCY[&]P<\V2N-S ("-_J%CK52U&] M K12SXB55:#?524HK\7V^^7U3=?RD]RL-\F_5C@EC M_G#8BK0A(B%<"GK5$K+UUY\__Q39G\M?VNUHP"A/+J+W,FX/Q52^BSZ3E%Y$ M'ZB@BABIWD5?"<_<%CE@G*JH+],%IX;:+XJ&+Z(W)]WS2=1N ^K]2D4BU9?' MX;;>N3$+?='I+)?+$R&?R5*J)WT2RQ16X<@0D^EM;:>KT\U/4?R2,_%TX7Y- MB*:1Y27TQ4JSJY9K=]/L\NQ$JEFG=WK:[?SSZ6X4SVE*VDPX;C%ME:5<+57E MNN?GYYW\VU)ZI%Q-%"_;..N4W=G6;+]E ?U.3S2[T'GW[F1,3![VVF8BK\+] MURYE;;>IW>VUS[HG*YVT2O@Y024Y?:33R/VUT=NV.F'2*!8SLW8AZ[BO.WUI M=TG;U[S@7-'I56MBXK6MOW=V^K;[QM7^ZY[(K!=VU]3,[5FMJ+/7\D)1387) MS=[9#7M%Z,K8'8HF946N?7C?##-.OMEANE';[5U9:ENS'POEIBME9[B,]]KG M+@KRP&RY1^>L-8U/9O*YDU#6<0#CNZ!L$\W0O+;M)ZX/ TYFU3@/)$">70R@E6ZPB+ZG M.E9LX;C4@-U3 OGV4/E6>&L850-Z_8?*N\H:$^>^,*$,57T-('XF!L-]@PO8X1.(] M5D1HYOA @!^K@<1_1[WP\'A$0CZ:4\Y=&D<$:"^OT@.Q_X&)W>_S%8"_?7;G M=WMJ@;/?*0+$__:UX#]RBQ2!!ZJ83.PI70'8'XF!U,\QJ7L3'C=-]UL:=!&/.DH?6VGPEV,]>AOT,CATE%ZVUB8F];S_>J[%< M>IY >\50Y"BY:(U%3.#YF>9>/2CYS(IY4774CTI T2.FJ&&SJ#M\<9*'[.VE M$LH;,5VM-H?)^4%J0_A_;%%W)5FMAS)'3%Q#1IN^P5C$W=VT\$TE.I! ^:+D MJI5VFD;J(JPH\>^^^PHH4)0$M,I,PSSOI'OV,9#_V6 7EBI))^DPU/?"Z MJ<3:>^CO? V>P88RK![::!CC-\6,[4%?IFDF-O=H/$_%/%(H7I3T+VBO8=0C MR=WL=B9FG^P5HF*$5W.NTD$AHR1[?F,-$WY0U$6:VLON?!Z76VN@[J=3W\@; MTD.)H^1Z]49QR0^USJAZ*?^*4M HH*1]4---CS,TSNRPM^[V)F.W8L8SRARI MH*Q14CZ?J8;9?I9C1=QZO=$ZG4CN7QY2*8021DGP M8:AKS7CVJ\!Q(H6)3, MKM(.TIAPNXKG1,RH?_9"M1(*&"73"YE#&WMGH+%W]L*Q%R7C\YE"8EO,#;=' MU/V$LQGQKR0+%@"OL\$D'K#:]/J]?,F/6\FMTKP? _NA&KM'"@6.LT0R9*]I MU%G"#$V*+@V8("*V*=5V79LG.Z\O!0T SAI*H&F4V_O?*.(M H(#Y#K+&+$H*ODF>6DLHG@BK/,>"10I$C/COTV,.9>UE,:MZ> M>XI7=H2(^TI P2,^1 R;19J?9JCK,WNF[XDAFQZ&^/M*0/DC/E ,FT6;/Z_Z M]L0SD^%GY@="*&W$J;"5UE @CU+"^4VFF: Z.+8<"*&0$>>\5EI#@7R;4C6S M@]H')9=FOEG;&8+M*0"%CCBS-6@5!_[JQSKR8OU;D'R%&OQV D3L7I-8K]V( M8S>1HCB3BX0H#_60'LH==6&EWVC#Y._-G*K=ZZ>\,T.;MX4F/=27@D8!)5V% MFL8YM^ZLY ^>6O=T4-Z(B6F5,9PU4]F$LWC )0E>E^_)H'P1L] *6RAX;XAX M4MG"Q.L')6-*W>,3O3W: D1L )H2!#STQ>AP+E=(-/4+2:2\=-H;DWK^\SD M;S"U_0O>- B6@X8&T]VW+;N)+OJM(_8+UQ*JF59,F. MG?B2[/J:\983>VS-IORT!9*0A E), I1?/UV]T 2$I6,F>RF7-D67F(;8H$ MNQM][T;KZ)?^AZMWS<;1+^?'9_"3X;^C_F7_ZOS=T9;]"9]NN8^/3J[/[ME= M__[J_.W&0*7Y >MULYSU92(,^R@F[%8E/&W9"RUV)[0<;,"#\.C-7WWND.7B M:][FL1RF!RP4:2[T(4NX'LJTG:OL@,$2Y85 Y;E*Z-K&NZ.+ZX_]^OO: Y[( M>'KP9V^D>XW\0U@ 8:63=\_3P&2'1ULG0!%<%W[<_#!*%EH"DW5G,=1R./K9 ML)]_'JTD^@J,_N;D_?;HBO^_OMWO]VN[W.[]EP@QU?]=]N;"P9 M"7\>D_K-^"?(UC\%'Q"ZV_.S3]?79\W&Z67_OL5.C]D6.SX]/;^[^W1Y>XY_ M%$. B/5V6RA<.R@H<+6257:9AAWVXN/QW=GQKP]#F_>\E" M^PA3F= \EZ ;9$I+:I&H7+"0ZTCRD"4JE3F\S8@0?Z@!/)F:(@%],1(\SD=P MHVBQ7$5\"AHA!3J'(B+M,O :H]G03F4,'-P#4CQ?G.*!10=6]Y#:F:("$FD$ MR_QWD0JVT[4DZZP.PRP6@/[QR=4Y.SV_NKJ[.3Z]_/C^[49W@_Z^.3X[\W__ M99PG,LI'>&MW$Y!3.A(:$8MY9@ @_]L&>6A'_=N__H*QT+F$[?.4!)VSX?R] MH_[9#P/<[6SORO2GDOW?]_=>[U=T[Y_]?\#\FRVY$VH+H'9V_-=>^^(>9$2+ ML4@+P88:U@NF[-5>9W^3W5_? _'9LYU.E\%+8ZG20Y17D.\"11P^X]$8A%+ MKQ.0<)8I(W,Y1GDWHT&L)G7:P'^WR\(5?Z/T+347/(1U97?E,0GGK0@+K4&F M+(AY:6S90 CK&H?P5H5V,A)D> V/<44GCBB!+-=@YM@(8C.AG\06KP5O&7?E M<0E>5("#:0&\>_^<)]GAL3-ZN][HM5BD)BG;WMZT?JX&5Q)N,3P1#/Q=J2(6 M2RYTD$T=XA@VL"/M9>/CK;P)^-@Z@YVNBSK)!UVWE_,"%N4BW_W M$XH,]O_.KDR_46Z@BS*-!"[?MDGO=17N!_ YTYUFXQ/_PKEAQW'[3D:1_-*J ME]@N\/W@+5'6@)V>7V,Z+DFP\!FU?#'MNM!S]:EZ<0IP_0QZGC-C*^HFAWLH MEP?A#D8W'?9)-!N&3]#GPF([.%P*EG3I/Y%21L(8RL+I!9A'D_AQ2(Q-N3"Y3-=( =Y6(%>?$A/-!L[C= M(HFU00GO $!F/$Z5-AOSR(*[RC,PFU]EPG,!&+WN;EHX>,K$6,5C!-3[LHG\ M"APCM'A(-(VP9@"US?(@?;5$SS8%VH=:<*(UO E+*!)!@5>[=5ML@C>" I<9 MQ[*GR\Y&WJ03T1$#4/.H8(+85B9GT4,7/ *S6,!?(?T00Y6^:.*$ @N,7O/ !8HR)PG(A59IE%IG#W7 T8 M2[P^F!BHL#"H9C,M(FDYQ=6(;84)>(Q>F(ZHSA3!3G!#^ XDL-JP5>8-@. 2 M:53QJMU^C9M/G ?"#7P#7%F5FF$O(M I>DJUY&IUW$Y\I,,N;>IA4.2%MOLK MTK$TR,C$H@XIH$&B(A$[P@,_\XR#EI#"6/,CDDQ-8%\+Q >VR2!GUR%!IL.: M'# 2 UP$$ ;$SH("U 1X .E/ )IP]LGK]$.U8\0B48$Y%"H5,BX CI"2\: M2PSE(IYSEBG8%:<, !!;P2/VLH"F'+BR#EEFFW;TS$[@RJ :9& K[G0C7,/] MCR4RL(4EY$Y%8+$00"%$0:*-K&U9 $3O7"GUF<)36TLTKGT 8(?E3^^I9M\B MFENF :[BF#<:P*7V0,41^DI>1)W&PT?QB<5=" B6<;P!NE2#&F\7F7L&E&X1 MF%#+##]N(XB@JFS7 S!6&(I8D.C9]5UP72D"JMG4BC.1!AW.61BCSP&(C_ B ML7'. V#E?-IQ#1>K8T)7TB4H?8%*N\\8>]C3J AS6":0RF1D9#)0M*!@$JLC M+'-X1]]QJE7DH#^I)R;)8A))#IJI6M"_T*"0U'2YM1/@F9 4@ADD0P%,*21& MD?E(%09>2>* I0S4%=8]4/8Y6,F06]O_8-W:=O4NDMPX(KAB' %'TL1;&3- M2.FAC2]RA+@MHB&I'!#1<.3=)V_,K&V7"2.+%HD!.#JDHV(D+:A[@>1-T(QA MCQ(HFF$*FE>&EM)>UR%P8%218@)P8-YY<]XAO:5.)]1".;H47M=X['WS5*Z! M.:R! -!!DSAW"9S%9L/W9>6.!N23H?&V!FS ZDJN4EXNAU?W2@QQ;:MR3EIV M,0 NB*49$2W1"4.5*B-P)85M V'8!])L$.<_$14'&/U;NPU!I4"K= .,?0@+ M?"G 6\<'6;OM(^>SR__Q8,PU5.YA0Z5KK_+73F) B/4ZNX S41DPJ;J\ZEU= M\UU?[AW?;->::^MZV))8I3(6)"AFR1^+ 3U1)@5J2U<$\_&QCXV/MH 6"\@2 M@#G_W X$2#I DQ$MZ\VH>P3>S2P576]]U:4[LWIM;[9P<^Q^_ 0V7-O.[S:U MNFZS9J/*MOP"3FR,APE^;JOWOQS;=4?FNB/SSRMR9&TM@#YNB5SOI>N[W/9I M_ZKSA)RM9]N=;ED2P) 1DYH@6T\B#[VN#BSCKCPFT:NUG]@0'+M*\,0*>@,3 MB)ULZ"\5#XRBXX2@&ML9EK#9KI60J7!,<^439AE6L*J="C!N?P= M5Y''W&R9OH!G9W*""%0,OV)F$Z,Q&10N%U?E)>DI=S_E]NP-XZ^\LZZG+@J$0'$/]?^<%RS4<4]9&1<9+2.@=8QT-/2 MLF5*P)Y*\U44=ZITMDG1+.XP)$V\W7E3Z50M,DSBII05I7QEKTLI2\/.;#G\ MCE+N+MWY)$SOVB%:QEUY3*(ZTU&%I=>&&HI(MUHL\HR:""?9$_ MA6"G#;8/6T&JL+#(4::IZ-9 @?JSP#"P[R&U*B$]2&R7'HD[V5 M_/;MUFZW:]4#&G1I\K4Y7S).6 OH4FX+CF:KN<>9X+F32^J] DF+8U&;*H'] MC:SLXUK<@&:[J5E,?:RALIV9M.B3V/ZU4"[CKCPFH9P)H<$OC30==:"&0NH% MK(]/HKZY%MU3/[G@VKYM=[7&\164Y=)LI&(J,)93+*@S[QO9K74%X?'ETR\@ M9&HV(I%S&5,E">.===X&."0O]MTC^.#=^2F>N[C KN1> MM_VK5>YC6)MB*PB'\)0#I5 GDTG'B+ S5&.V\E/S'B\^1R?O+JH9B=\9JPI, MDPZ$QFY4.N;X%,I.CQ>?#[6S=]5!5HZI4;^)X3?/JMK^E/E#JG0>11IP_LSL M:$WV<+)F=59QYA2C/6CF3@8!-(%GL8)8K,..HTAB=A=/'3F518<32@UCST[B M2R[3L3 X#O36'TBC^:"N0WV1EIN( '23.&@V1GF>F8.M+=1107DTLP,.[)9T MRYJMU6&&'V@WWUZWFZ_;S9^4, ML')$>6@N<*K!"N&*=SA<9\S?BU[YUTW_Y>J@O()"W%<8]%QH83>2O7G]NOVJ MN]ON;??V5@K12SQ-F7+K,CFF_8\>>%Z]]MZ;_?:;G9W5PO>3"$*.AT=_N[VR M6^M=.3I[WPE'2A?H?,;DS.&Y2C[0/!%;$_MD9Y0G\7^Z/V3T]G+GTU7P*?VP M.E1:-7'V?KYI-D*>XB +F=))>C>^!!Q]MYU@BE@BTP*K0=87\_,&XI:;VP$+ MV"\;@+B!PB(ML#X$(<443\FF."J23CCK(4_E']Q.<^B[5>B19B.@EOF89HRT M58KC%E0DUCF.I<7G&+_\(8OYU$>&Y69BBJL*+F=;$G8@9BXT.'B#W(6"T >Q9\UU=&$GA-/_8."YYJ2EQ6?&MX 0@)CJ8Y$$.#O=>QI[>UVP MOKL[*X7V(D^#W(S>=OOUJ][N2B%K-[;9."8SPR[/[.;V=EZ_ZNYM;Z\4KN=? M,ZEI7]VNNKAN>]\?4^OU#G;WVJQE:YKLH<^V M=M26%A_T6!*;NK;1I]-@[;"[K1\Q',6*98J^"%P:E6 [3 8:9$" M&'#L44O C:>Q6#(O0(,,''/$CCFJ]W5*QHG]Y,'J0\PRR!"GK>+D4(CX#.B5 MS'*>G0OFWD_S"&DV) YYPRE9;I";1-3=[#((*+D;,H@*?"A2FOXY91*[8N1 M^I:+P@@:)TJI$(5#$-U@.<"JY;^LT5TR$-/&T?S5R<*+$!_/7PL7W6C"D8@* M, [^@V;#?6*QF+^_&G4Z_PD$P!1]SU\/1(S#9^YBOC/&DMAFY[!DV.Q3*1E@5;]7EWJL!?R)<'K>$@%O]NQN9;; M$#'J^*E,/S)VL^$XSWWK)C%89:@?K@4HV:7LY%<[E1-?"^P,XM^JC[MS]C0! M:XI%,I=!0R# L1C$Q5=H7_98FC/X:JIW^&OV7N:C=II^I!G-/P461B] M$* 8O#F2V+F01J:ZP8[2(X)Z]J@Z(R0.2": W58]Z+RR>U$]@2?>P 7$::FM M9N.%'+]T(TV'18QIRRFE+!-*05IM4UO6[:G=-"L=U+KK+M/NO' KUI43=57$ M4]<36-]G/J-N2PU&VM:.A$4NM%OB\80E"&X>J+'HL+LB''U'HY)R0^V<"&X' M*[JIOL1X!4@2X '@ HUKW^+:FB$4(S?42I_489&@EQHZ.4#9PO4#I"+R)$ ? MB) 7QLV>10#LI-8BL^+\8)OPW"#B7[&<@=UY("LM1IIJ +_,*G"OV%PW])Q= M0 !,0:O8B; , MG.V9*C*76L5T4*+#CHFH9?^.G[\-L!(K#)A[I:EHG@[\""*Q"/\%DB41<4(LSF\2T'@.-0:-"-&@^Z^,?^5,,O M8CL V$[Y)2$.:"MXU2+EM ;.LZ8ONJHF/4/X@D->"4U0%K;O"D !QX/$PA@5 M2AKU4[9VUK6X.VXWT\+O9P-)");\I.FJY=C?@\B2[HUC^:60 .IT(6K(MC7< MW#F@133P/6*M&?R&R, I >M4HS,#/K"S(^PKGEXPO;O%L%6)7">'*>IWB&#I M)797RKFTI%#]J4(T\2*7N1L<8'<8SR+K0.;6J-H)M7#+L+3@*OS,P#&$OPEM M.OA4(Y/=I(5&@LL8K00>PO!'++Y+*VO%R6B6?B65L8RH- >YOI0&0)HXGQ)9 MMNZJDJ*G =RV'\^?F'S801R3<:UW"M,;<0@\3I,G_8N*")6?=L/ ^0P:;I(X M'N$"_:R0;?VH:QPI7T\ D 85I-%4$#L:(WUL(R&]Z#NRC>/R-3428A/]($;% MBX^0FINW(NBH. 7#[4S_LB 4N3/H%'>XB&.=%%A:?(Y.Z @B1GSK('^9\?%E M56Q(=\V]JX/M-SZ MI?_AZMW_ 5!+ P04 " #$1!%7H=$7/!D2 \B@ "P &9O]W'GNZ%R!)( **G<0T*(M6,!J^\79)!O8&A+<;!#Z MZ^_930*$EZHM6K4\+RK9S7G?L^>'P?\.>C0:$>=1UCA)J2DD@XABN29W. M4<+G5G(_\;_BYL9AET,_Z.MX1XDNY_U".GU_?Y^ZSZ1=25>FY64_=^1D?08_S"<%E?5= ,')+KX^;' M27>^N/^D:YHS['B6RWJ8@PX%I%Q2T9+:[A20I$>,&"#XG.JX@P?A["_H;5'.$8"2I+<^71PE"B[#B<. M3[9'?9"W$7PZ2G RY.E@%*;%>^D0[.&_DDET0HEM%E"+\ -4QSU20$-S>(!J M%?G'C:*5;RY;_VB5TU+I GX)\E R^=BW,_D;P>Q-G,F;B,DG0,J6QV_]RNNY MR@T!"P,.X+^J S( VCT&25=NU)O0.00PX=%38&@WK2YFQ+O1;J0O#(!X\ME3X%0$ M+10H88$!%I"J]#EJTQYTJ9-[U'1[V-D)'NP 8Q: MTM1-.HC>,ZG7M_&H@!S7(;*1#@O"9@D3@T%^HJ9)'#DTQ$?H6/=[ ,L(K'[( MF\)[E+R&)6Q%."P84<@!3@$\H86%%I H3DS@,!T#^^N88C:1*$JC6 @\'6-+ MX (?1QA,N\0+>@A76O#D' E(D9SX"EWI)W5NC)+1L$@-/3,1-G-P!4<)C_;Z M-@F&?X@J#CQ Y[D^B[!!-ZGC0L@FHN8B&^$%L?9.J:\U3 S,]X!7-2G+ 009JTS;T&ZEOR4M0R M2U:,@.AA*,:X;'V'!H*%(34GS1[!GL](,1Q[!>@3 8N:XB@$M"7P@X&\%$4H M!-GIEW%,',8<'ACHAUF'.DGN]@L(0(P?Z"[G;D\^2Q3_\V]U5SDX3/>++XYZC'1JSFKZ-DE> MX(Z<6J>GC4= /$#WU.1=0;7R3R+VMNXRD'/P]K&-C5N4!<8\UZ;F 0H;(TA! MNYK*37H(820]^@-F4G5::$)GX<\I'M(Q)EY>K%X?.]/XDA;N41MFW E#RB+65D3UON1?+U[6:^UJ97.CU2ZUJZW#M%Y\@TRTJN7+ M9JU=J[8V-TKU"JI>ES^4ZJ=55&Y\^E1KM6J-^AOC3 LYNRJU/M3JI^U&?6=S MHU)&FI++YM\8+V][@)PTFI^ 4@E2S.XB+<@K.9GM)),5U_!%4"LRS1MCG)A- M4K0?]^K75NU[WZ]>9@#>KT3.TS@2Q?WD^6S8/);JVBQ>AFHP"W XS6J]O;G1 MK%XTFNVU[%]0]A<^\WSL\,T-[D(_0Q3DD)I!+D-J;LO<1JZ%>)>()I]13@%^ M=6ATL0-A1LG@HEG-9[)KG;T4U2([W-P L3/2=QE'6^*!4 /!$/H3CR,R *1A M,S&W"VC6X69F'.Z%S"VK0>:YV/.>=\LG]]SIN;??G^1Y@R+O48(.><$$Z#WH MVS7Q: 34$F>19XX1DRB6_(X//*FY'23@+G77;TN)*S:]!_*39Y_79PWL)#2P MH"+6)!WJB9(_%U7!Q?;UP?[ E))E7_)?G-@7H4H4CVN-=K-6KK6_;F[4ZN74 M2\SV?TH9[\FP)"];U2$V8&(22D;2X47*1=A#7I\8HH)G(@JFQST$DQ+X.[;] M/IA?K$B.=9L -MN&YX9<.%42\G,?FV;T^ H.BOH )W MR-G3$0P(X]3 =B0OD&Q4SSODYDRYY(&*R)-8RFC_O$ 0->O_RC'_5W,,E\%D M+!<[6QRFM7*PR%=VS27NL.2>7G_-GGR\[^[]ZG0KUF%%"9J3/G,'8@S%Y]M' MT)8HULD F_@Q7I.;\_I\O+9"ZQVK7BI]K,3GU^',:%O$S+LQSFK,.$^H34"O M.F&++=&_8$/*>J??GFB)LX8VP2/68]1D5MG;5=>&]9X,2XD95AL/:^$JFR&] MR\^L3&VZ>]>\M%^W?LO(EN!,%#-*4LGO9W*9QYH<_&#//=W]3E$>Q/0VXYHM M.C,9]0S:5!\<*U8U".%]C9YC4VN$Y99!SOTAWPX':S^KJO[ MXX[L[[3GLMOK44_L:7PO9BNFZH"!P'VNC?3-&VFMV0HD4>WU;7=$V'NQU?AT M'UJMFYHSV)B\+@LB]6!!9,DU&/"_\]9$Z1%T<0+9^Y!O' M^Q>9O+__6Q'D H2)HJ9D-C>:Q+QW71.UNJ[8F7B!V>T]'BT))W?F:N[* WQI M2P+C.^]LH.Q:]FYWQ7QIB6++IYR@745Y]V71!8:67Z20,OS98&WWWEFL#NN+ M/AHLSI>Q(4,L1OL@KD#ZAA+2DQ.^X>BN1=J M]9O^O"6FQ40EBF70-@!SZ++ZTM)UJQC<"Q%S.B"H8<%$3+SM]\/U.Y]L M*^& $BZGQ A>/H3N.HXZ:*MG%?=IZ[^3(32- R+2W9RRO630S.\0BH*"CZZ! M[8NNZ_RT9'DW4#]_ORK7]X;D%VF=Q9,H[F>TI+JK[?X5XUQP,UE)_<^_]S5U M[P"&/2*90>!#[!]46!%&%0+TC7)ZM;?WN9:_)KJGR6B)Q ]$+:Y M49=KN@P%GU$XLX!!6:@L-Q=!H"W"!/01>QPUY5Z6M64MH/J[[T'^.UHEV>4N M,6YAM'<)PGV([/J,BBU&NCM$.K'=>Z$DT2ATA_:3Y\BBMG !U -_P(EC@O*X MBSS:\VV.'>+ZGCU"'F3HGC62;X8ON#KP@,.BKVR86N+W 0X8"G9&4:/EVH!= MO"C"32I*;A[:.J1%CQ!QKJ%X2AS"("*I.0###ZK)I926"LC>+KPY3?R-FP"> M3+"2TG+4>79=+-OC=,4H!Z,796#?">M0WN+ Q.1Z=\!,_7L9__(F.MUU;8(= M>>1O.F192(:PH/Q>-GOPT+:YU55*GT'R(6L!@4:,0=0/MZ\*AR/.OZ"LE@M< MQ^RN5;%9=4O=0^63)@*%I*#C]MM8\7M^Q_*JU3]/ZU^EJF6G)5JN+JY=SEO0_]KEQ%R.&KJ<"T9$?"$.^,LS5"+49PW+6E:(J9&& M=IP?G=6SG96[GN6TO \7!/PEC2D&'Q?]J%DSJ6WIVX]S2$'?;?37&OK:)[T9 M52TK7<_X@9KG^80]Z)F(E;^^(Z/N[?"Y'=,<07^U>\J09';+>)Q["OLNB9A6 ML(WCSU9QGH7L\"%UQ+:8J#2RTLAXG%!O;@3%.L*(&=/T^!"IG(C"VAUHMX#J MKD/>20WN=\D.?KY,Y:KFF&)(DLT-?80,4=P5M-RB^RZ1NV]G"J_40X 81K4@ MMX,ZS+WG73&T^Z(6BSUD$HLZP;FKH.2BY!:<$IX<#LZ@+2'$O0-9=E%RFP*;6QO;BQE8-[69S(VXX(6=+ MBJC!_HKHW5/Y9CEX<#\4=WYT;L&I"ZZ-V#!Y@6MS7#F5^1Z1O8"#<%E+7%Q*Y?067,@F#$KB MLD?2Z.\IX!9^T@$&H(F1 ?7@1?"8V#%$"0D;\HI/0:JX-M;$S/2"!2USV42: MV<+CB73:$Z8"[8U-\K>5^ >O\XK9SQ^^I"MV^&KA\:RI:[RF#?)OOZ0KKB_! MY0$ N/-%E@ O!BS+E&9>_C\Y_S;#R:[D9+(*.KWJ.;LJ&LP]G(M2'('(I#G'$'6:"!)M C$=%KELE^J4HWP^I4HKE/NFHI.B85?(K2%>'=^G MO,YD7XCL=I=L;E!G_-T$HL@A:PIEGS%QK5:P%7%ZYVN0($B=>J&:=X1.=2): M+9\YU!,6(%3M=;%MR^Q")\@DD+28D=%:U"9F:++"]#8W(!?HNQZ0#\8US@7V M'UD=V1&FAGO29G=$)N**6L\])"/(\_7O $ZD& *03;%.[0"2A(TA\ K1"3)" MU!Y2 W-5-4A'MK1%-\--U7RF\:<0B!5-2U6DZ#@J(DGYBOE$3B7!D' D:)$K MR:$L-V)#HRGPL2O0D>GEF192MQX)!9GC]&))Z$$ $ :$G M03*MBS,KLDYS(OK),>"=<6&MATU(.V4$)Q!ABX?5-C.\LDURSD*+ @HA%[2% M X$F@;43[F>DT^?(D0WX?!&]@9 \W^AN;H3;*;<$#F>:>ZGA.>-% &2\=S/$ M88^V=\"*#=(/+E>2TM6%84N7)O9O$B[,$N0 L@DO7S(FN,2HD>2$FSO?B\=Z M+^'DRC9;/FLLF4\I*GJMP>0X6@P(:D5.)(@E0^_D_;D ]YFYE*C[Z"FX[4E3NCT'JF+\!8X7U48S>Z8L*??L_4;TA_Q1*O$,]@ MM,_E%2JO]QJF57(M0MA7-\6M<#?42BT$H^#[B,@PGT^JJ2[OR?TG$"P1PC6-)Q;.&U!+C N'A\EM"?+=)4D3G__A2 M M^ Z,UYD3C6TI)W=HO<9<9'+!]JNG,+OWS"2^)M-YI%=YB=8\6TUXZ M(/8*WV&(M$IVLD5APKD3-[:L#6I-ULQE'])* E*F3&5M)FNRXG=446(%E$PV M\07W3[)W7I7+'*"&7"SQ"L'M:.LBW0-%NE66T9:=4TCKKCD2UI7N\IY=C*NP M1?@!$E?>%=#0'!Z@6D7^<:/L']_(LR7!76:2+/D>.1N>?#>KYYW;TN>FGBY9 MP^]:X\I5RX-/P[NO'>\S/=N]OC[_=&9J3HF/7;V;<1J#:KDQ M=/4K_[9Q.OI1^93]:JJ7(_KA]JI\_MW'9YE^G9NEP5Z/U"^NO/:Y;V7RG58_ M=_QC_\=I]O(LY^JFIO7.FYW:O9.]OF^U+T\:U:%3,5K_+;/<;NO\^NIXV+._ M=-JUDP]GMUCU.Y>#+*[>9NY:KL6^?,EI3=;"[<\5>M5)CTY;M:_-#^?==N6_ MYWO=UO!CLUVY.QN6]#[35A8&!_@H ("& M 5 " 5L# !B=&-Y+3(P,C,P.#$U7VQA8BYX;6Q02P$" M% ,4 " #$1!%7ES51!5@' #95P %0 @ &,#@ 8G1C M>2TR,#(S,#@Q-5]P&UL4$L! A0#% @ Q$015PTFMVY@%0 QHX M H ( !%Q8 &5X.3DM,2YH=&U02P$"% ,4 " #$1!%7 MH=$7/!D2 \B@ "P @ &?*P 9F]R;3@M:RYH=&U02P4& 2 4 !0 V 0 X3T end